Endovascular Engineering (E2) has raised $80m to advance commercialisation efforts for Hēlo, a platform for venous thromboembolism (VTE) treatment.
The California-based company’s oversubscribed Series C financing round was co-led by VC firms Gilde Healthcare and Norwest. Existing investors, including Santé Venture and M&L Healthcare Investments, as well as the two existing undisclosed strategic investors and a new global strategic investor, also participated.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Hēlo, which obtained US Food and Drug Administration (FDA) clearance in December 2025, has been designed with a dual-action mechanism that integrates aspiration with mechanical clot disruption. According to E2, this design supports improved procedural efficiency and clinical performance during treatment of VTEs such as pulmonary embolism (PE) or deep vein thrombosis (DVT), while surmounting the limitations of legacy thrombectomy systems.
With $42m Series B and $15m Series A1 financing rounds completed in February 2025 and April 2022, respectively, the latest funding round brings E2’s financing to date to $137m.
E2 CEO, Dan Rose commented: “This is a pivotal milestone for E2 as we continue our mission to improve options for patients and physicians in the VTE space.”
Rose went on to add that the financing would enable the company to build a strong commercial organisation while “continuing important investments in R&D and operations”.
Recent dealmaking in the vascular care space
Research indicates that VTE is the third leading cause of vascular death after heart attack and stroke, yet public awareness of the condition remains limited in contrast to the aforementioned conditions.
VTE is also determined to be a leading cause of preventable hospital death in the US, as per the US Centers for Disease Control and Prevention (CDC), and is the fifth most frequent reason for unplanned hospital readmissions after surgery.
The past 18 months have seen a duo of significant deals made in the broader vascular care space. Stryker completed the $4.9bn acquisition of VTE specialist Inari Medical in February 2025, representing an expansion to the medtech giant’s interventional endovascular portfolio that gives it a foothold in the VTE market.
As announced during the J.P. Morgan Healthcare conference in January 2026, Boston Scientific agreed to acquire Penumbra in a $14.5bn deal that also bolsters the company’s position in ‘fast-growing segments’ of the vascular care space.
Key products that Boston inherits from Penumbra under the deal include Penumbra’s Lightning Bolt and Lightning Flash computer-assisted vacuum thrombectomy (CAVT) systems. Used for removing blood clots in the arterial, venous and pulmonary vessels, the systems received US Food and Drug Administration (FDA) clearance in 2023 and 2024, respectively.
